Danger of Withdrawal of Vasodilator Therapy in Patients with Chronic Heart-failure

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 1980 Apr 5

PMID 6103157

Citations 4

Authors

S P Hanley

A Cowley

J R Hampton

Affiliations

Soon will be listed here.

Abstract

Ten patients with severe congestive heart-failure were treated with a vasodilator, prazosin, in addition to diuretics; their exercise capacity was assessed by testing on a treadmill. After the withdrawal of prazosin the condition of three patients deteriorated markedly.

Citing Articles

Vasodilators in heart failure.

Breckenridge A Br Med J (Clin Res Ed). 1982; 284(6318):765-6.

PMID: 6802217 PMC: 1496367. DOI: 10.1136/bmj.284.6318.765.

Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Stanaszek W, Kellerman D, Brogden R, Romankiewicz J Drugs. 1983; 25(4):339-84.

PMID: 6303744 DOI: 10.2165/00003495-198325040-00002.

The treatment of heart failure. A methodological review of the literature.

Guyatt G Drugs. 1986; 32(6):538-68.

PMID: 3024949 DOI: 10.2165/00003495-198632060-00004.

The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.

Markus H, Cowley A Eur J Clin Pharmacol. 1991; 40(6):535-8.

PMID: 1884731 DOI: 10.1007/BF00279964.